...
首页> 外文期刊>World Journal of Gastroenterology >Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.
【24h】

Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.

机译:明确的放化疗治疗鳞状细胞食管癌患者的生存预测因素。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: The aim of the study was to evaluate the predictive factors of survival in patients with locally advanced squamous cell esophageal carcinoma (LASCOC) treated with definitive chemoradiotherapy (CRT) regimen based on the 5FU/CDDP combination. METHODS: All patients with LASCOC treated with a definitive CRT using the 5FU/CDDP combination between 1994 and 2000 were retrospectively included. Clinical complete response (CCR) to CRT was assessed by esophageal endoscopy and CT-scan 2 mo after CRT completion. Prognostic factors of survival were assessed using univariate and multivariate analysis by the Cox regression model. RESULTS: A total of 116 patients were included in the study. A CCR to CRT was observed in 86/116 (74.1%). The median survival was 20 mo (range 2-114) and the 5-year survival was 9.4%. Median survival of responder patients to CRT was 25 mo (range 3-114) as compared to 9 mo (range 2-81) in non-responder patients (P < 0.001). In univariate analysis, survival was associated with CCR (P < 0.001), WHO performance status < 2 (P = 0.01), tumour length < 6 cm (P = 0.045) and weight loss < 10% was in limit of significance (P = 0.053). In multivariate analysis, survival was dependant to CCR (P < 0.0001), weight loss < 10% (P = 0.034) and WHO performance < 2 (P = 0.046). CONCLUSION: Our results suggest that survival in patients with LASCOC treated with definitive CRT was correlated to CCR, weight loss and WHO performance status.
机译:目的:本研究的目的是评估基于5FU / CDDP联合定性放化疗(CRT)方案治疗的局部晚期鳞状细胞食管癌(LASCOC)患者的生存预测因素。方法:回顾性纳入1994年至2000年期间使用5FU / CDDP联合定性CRT治疗的所有LASCOC患者。 CRT完成后2个月,通过食管内窥镜检查和CT扫描评估对CRT的临床完全缓解(CCR)。通过Cox回归模型使用单因素和多因素分析评估生存的预后因素。结果:总共116例患者被纳入研究。在86/116(74.1%)中观察到CRT转换为CRT。中位生存期为20 mo(范围2-114),5年生存期为9.4%。响应者对CRT的中位生存期为25 mo(范围3-114),而非响应者为9 mo(范围2-81)(P <0.001)。在单因素分析中,生存与CCR相关(P <0.001),WHO表现状态<2(P = 0.01),肿瘤长度<6 cm(P = 0.045)和体重减轻<10%在显着性极限内(P = 0.053)。在多变量分析中,生存率取决于CCR(P <0.0001),体重减轻<10%(P = 0.034)和WHO性能<2(P = 0.046)。结论:我们的结果表明,接受定型CRT治疗的LASCOC患者的生存与CCR,体重减轻和WHO表现状态有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号